ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 3.62 USD 0.28% Market Closed
Market Cap: 383.4m USD
Have any thoughts about
ProQR Therapeutics NV?
Write Note

Intrinsic Value

PRQR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PRQR stock under the Base Case scenario is 2.42 USD. Compared to the current market price of 3.62 USD, ProQR Therapeutics NV is Overvalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PRQR Intrinsic Value
2.42 USD
Overvaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ProQR Therapeutics NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PRQR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PRQR?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
ProQR Therapeutics NV

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ProQR Therapeutics NV

Provide an overview of the primary business activities
of ProQR Therapeutics NV.

What unique competitive advantages
does ProQR Therapeutics NV hold over its rivals?

What risks and challenges
does ProQR Therapeutics NV face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ProQR Therapeutics NV.

Provide P/S
for ProQR Therapeutics NV.

Provide P/E
for ProQR Therapeutics NV.

Provide P/OCF
for ProQR Therapeutics NV.

Provide P/FCFE
for ProQR Therapeutics NV.

Provide P/B
for ProQR Therapeutics NV.

Provide EV/S
for ProQR Therapeutics NV.

Provide EV/GP
for ProQR Therapeutics NV.

Provide EV/EBITDA
for ProQR Therapeutics NV.

Provide EV/EBIT
for ProQR Therapeutics NV.

Provide EV/OCF
for ProQR Therapeutics NV.

Provide EV/FCFF
for ProQR Therapeutics NV.

Provide EV/IC
for ProQR Therapeutics NV.

Show me price targets
for ProQR Therapeutics NV made by professional analysts.

What are the Revenue projections
for ProQR Therapeutics NV?

How accurate were the past Revenue estimates
for ProQR Therapeutics NV?

What are the Net Income projections
for ProQR Therapeutics NV?

How accurate were the past Net Income estimates
for ProQR Therapeutics NV?

What are the EPS projections
for ProQR Therapeutics NV?

How accurate were the past EPS estimates
for ProQR Therapeutics NV?

What are the EBIT projections
for ProQR Therapeutics NV?

How accurate were the past EBIT estimates
for ProQR Therapeutics NV?

Compare the revenue forecasts
for ProQR Therapeutics NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ProQR Therapeutics NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ProQR Therapeutics NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of ProQR Therapeutics NV compared to its peers.

Compare the P/E ratios
of ProQR Therapeutics NV against its peers.

Discuss the investment returns and shareholder value creation
comparing ProQR Therapeutics NV with its peers.

Analyze the financial leverage
of ProQR Therapeutics NV compared to its main competitors.

Show all profitability ratios
for ProQR Therapeutics NV.

Provide ROE
for ProQR Therapeutics NV.

Provide ROA
for ProQR Therapeutics NV.

Provide ROIC
for ProQR Therapeutics NV.

Provide ROCE
for ProQR Therapeutics NV.

Provide Gross Margin
for ProQR Therapeutics NV.

Provide Operating Margin
for ProQR Therapeutics NV.

Provide Net Margin
for ProQR Therapeutics NV.

Provide FCF Margin
for ProQR Therapeutics NV.

Show all solvency ratios
for ProQR Therapeutics NV.

Provide D/E Ratio
for ProQR Therapeutics NV.

Provide D/A Ratio
for ProQR Therapeutics NV.

Provide Interest Coverage Ratio
for ProQR Therapeutics NV.

Provide Altman Z-Score Ratio
for ProQR Therapeutics NV.

Provide Quick Ratio
for ProQR Therapeutics NV.

Provide Current Ratio
for ProQR Therapeutics NV.

Provide Cash Ratio
for ProQR Therapeutics NV.

What is the historical Revenue growth
over the last 5 years for ProQR Therapeutics NV?

What is the historical Net Income growth
over the last 5 years for ProQR Therapeutics NV?

What is the current Free Cash Flow
of ProQR Therapeutics NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for ProQR Therapeutics NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ProQR Therapeutics NV

Current Assets 92.4m
Cash & Short-Term Investments 89.4m
Receivables 770k
Other Current Assets 2.2m
Non-Current Assets 14.4m
PP&E 14.4m
Current Liabilities 39.6m
Accounts Payable 31k
Accrued Liabilities 1.4m
Other Current Liabilities 38.2m
Non-Current Liabilities 42.2m
Long-Term Debt 11.5m
Other Non-Current Liabilities 30.7m
Efficiency

Earnings Waterfall
ProQR Therapeutics NV

Revenue
21.3m EUR
Operating Expenses
-48m EUR
Operating Income
-26.7m EUR
Other Expenses
2.7m EUR
Net Income
-23.9m EUR

Free Cash Flow Analysis
ProQR Therapeutics NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PRQR Profitability Score
Profitability Due Diligence

ProQR Therapeutics NV's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Positive Revenue Growth Forecast
29/100
Profitability
Score

ProQR Therapeutics NV's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

PRQR Solvency Score
Solvency Due Diligence

ProQR Therapeutics NV's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
43/100
Solvency
Score

ProQR Therapeutics NV's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PRQR Price Targets Summary
ProQR Therapeutics NV

Wall Street analysts forecast PRQR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRQR is 6.83 USD with a low forecast of 2.17 USD and a high forecast of 14.7 USD.

Lowest
Price Target
2.17 USD
40% Downside
Average
Price Target
6.83 USD
89% Upside
Highest
Price Target
14.7 USD
306% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PRQR?

Click here to dive deeper.

Dividends

ProQR Therapeutics NV
does not pay dividends
Shareholder Yield

Current shareholder yield for PRQR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

ProQR Therapeutics NV Logo
ProQR Therapeutics NV

Country

Netherlands

Industry

Biotechnology

Market Cap

383.4m USD

Dividend Yield

0%

Description

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Contact

ZUID-HOLLAND
Leiden
Zernikedreef 9
+31881667000.0
www.proqr.com

IPO

2014-09-18

Employees

150

Officers

Founder, CEO & Member of Management Board
Mr. Daniel Anton de Boer
Founder & Independent Member of Supervisory Board
Dr. Domenico Valerio Ph.D.
Chief Corporate Development Officer, General Counsel & Member of Management Board
Mr. Rene K. Beukema
Co-Founder, Chief Scientific Officer & Member of Management Board
Dr. Gerard Platenburg
Chief Financial Officer
Mr. Jurriaan Dekkers
Chief People & Operations Officer
Ms. Sheila Sponselee
Show More
Vice President of Investor Relations & Corporate Communications
Ms. Sarah Cue Kiely
Junior Financial Controller
Ms. Sandra van der Kolk
Show Less

See Also

Discover More
What is the Intrinsic Value of one PRQR stock?

The intrinsic value of one PRQR stock under the Base Case scenario is 2.42 USD.

Is PRQR stock undervalued or overvalued?

Compared to the current market price of 3.62 USD, ProQR Therapeutics NV is Overvalued by 33%.

Back to Top